Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2237 • ACR Convergence 2023
Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice
Eva Galindez-Agirregoikoa¹, Diana Prieto-Peña², Maria Luz Garcia Vivar¹, Lucia Vega-Alvarez¹, Cristina Vergara³, Irati Urionaguena⁴, Consuelo Ramos-Giráldez⁵, Raquel Almodovar⁶, Beatriz Joven Ibáñez⁷, Rosario Garcia-Vicuna⁸, Vega Jovani⁹, Teresa González¹⁰, Àngels Martínez-Ferrer¹¹, Ana Urruticoechea Arana¹², Bryan Josue Flores Robles¹³, Cristina Campos Fernández¹⁴, Lilian Maria Lopez Nunez¹⁵, Joaquin Maria Belzunegui Otano¹⁶, Marina Pavia Pascual¹⁷, Esteban Rubio¹⁸, Angel Ramos-Calvo¹⁹, Noemi Busquets²⁰, Ana Pérez Gómez²¹, Francisco Miguel Ortiz Sanjuan²², Rafael Benito Melero-Gonzalez²³, Cristina Macía²⁴, María Ángeles Puche Larrubia²⁵, Jose Antonio Pinto Tasende²⁶, Cristina Fernandez²⁷, Maria Paz Martinez-Vidal²⁸, Jaime Calvo- Alén²⁹, Emma Beltran-Catalan³⁰, Mireia Moreno³¹, Silvia Pérez-Barrio³², iñigo Gorostiza Hormaeche¹ and Ricardo Blanco³³, ¹Basurto University Hospital, Bilbao, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴GALDAKAO-USANSOLO UNIVERSITY HOSPITAL, GERNIKA-LUMO, Spain, ⁵Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ⁶Alcorcón Foundation University Hospital, Madrid, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹¹Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Hospital Universitario San Pedro, Logroño, Spain, ¹⁴Hospital General Universitario Valencia, Valencia, Spain, ¹⁵Son llatzer, Palmanyola, Spain, ¹⁶University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁷Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁸Servicio Andaluz Salud, Sevilla, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ²¹Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²³CHU Vigo, O Carballino, Spain, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ²⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁷Hospital Universitario San Juan de Alicante, Alicante, Spain, ²⁸Hospital Universitario San Juan Alicante, Alicante, Spain, ²⁹Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³⁰HOSPITAL DEL MAR, Barcelona, Spain, ³¹Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³²Hospital Universitario de Basurto, Bilbao, Spain, ³³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The EMA authorized Upadacitinib (UPA) in PsA in January 2021. UPA has shown efficacy in PsA refractory to anti-TNF in a clinical trial (RCT).…
Abstract Number: 2596 • ACR Convergence 2023
Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database
Qingran Yan¹, Cosimo Bruni², Alexandru Garaiman², Carina Mihai², Suzana Jordan², Mike Becker³, Muriel Elhai⁴, Rucsandra Dobrota², liubov Petelytska³, Anna-Maria Hoffmann-Vold⁵, Joerg Henes⁶, Eric Hachulla⁷, Elise Siegert⁸, Alexandra Balbir-Gurman⁹, Giovanna Cuomo¹⁰, Gabriela Riemekasten¹¹, Stefan Heitmann¹², valeria Riccieri¹³, Susanne Ullman¹⁴, Petros Sfikakis¹⁵, Francesca Ingegnoli¹⁶, Vera Bernardino¹⁷, Marie-Elise Truchetet¹⁸, Francesco Del Galdo¹⁹, SHUANG YE²⁰ and Oliver Distler², ¹Department of Rheumatology, University Hospital Zurich, Zurich, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴University Hospital zurich, University of Zurich, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶University Hospital Tuebingen, Tuebingen, Germany, ⁷University of Lille, Lille, France, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ¹³Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ¹⁴Department of Dermatology, University Hospital of Copenhagen, Hospital Bispebjerg, Copenhagen, Denmark, ¹⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁶Universita' degli Studi di Milano, Milano, Italy, ¹⁷Centro Hospitalar Lisboa Central, Lisbon, Portugal, ¹⁸Bordeaux University Hospital, Bordeaux, France, ¹⁹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ²⁰Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) with the current best evidence for the treatment of systemic…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Natalia Shevchenko and Olga Pavlova, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…
Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Kristin Wipfler¹, Adam Cornish¹, Rebecca Schumacher², Yomei Shaw³, Patricia Katz⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ⁴UCSF, San Rafael, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0308 • ACR Convergence 2022
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Joseph Merola¹, Kristina Callis-Duffin², Byron Padilla³, Cuiyong Yue⁴, Huzefa Photowala⁴, Blair Kaplan⁴ and Iain B McInnes⁵, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³AbbVie, Inc., Waukegan, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 0810 • ACR Convergence 2022
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
María Paula Álvarez Hernández¹, Alejandro Gómez Gómez², Lara Borrego Sanz³, Rosalía Méndez Fernández³, Pedro Arriola Villalobos³, Esperanza Pato Cour⁴, David Díaz Valle³ and Luis Rodriguez-Rodriguez⁴, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct…
Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Alberto Sulli, Tamara Vojinovic, Lercara Adriano, Emanuele Gotelli, sabrina Paolino, Alessandri Elisa and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…
Abstract Number: 1289 • ACR Convergence 2022
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
Suguni Aushadhi Loku Galappaththy¹ and Nicole Fearing², ¹University of Missouri Kansas City, Kansas City, MO, ²HCA Menorah Medical Center, Overland Park, KS
Background/Purpose: As the number of bariatric procedures increases, surgeons will encounter more patients on long-term immunosuppressive medications that may increase post-operative complications. Currently, there are…
Abstract Number: 1613 • ACR Convergence 2022
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit
Rachel Charlton¹, Laura Coates², James Galloway³, Neil McHugh¹, Anita McGrogan¹, Simon Hackett⁴, Melanie Brooke⁵ and William Tillett⁶, ¹University of Bath, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: To compare the time from symptom onset and General Practitioner (GP) presentation to referral and diagnosis for patients with psoriatic arthritis (PsA) to those…
Abstract Number: 1983 • ACR Convergence 2022
Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients
Kristin Schmiedeberg¹, Irene Abela², Nicolas Vuilleumier³, Johannes von Kempis⁴ and Andrea Rubbert-Roth⁵, ¹Cantonal Hospital St Gallen, St.Gallen, Switzerland, ²Institute of Medical Virology, University of Zurich, Zürich, Switzerland, ³Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) on immunomodulatory therapies have a higher likelihood of an impaired vaccine-induced immune response following an mRNA anti-SARS-CoV-2 vaccine.…
Abstract Number: 2193 • ACR Convergence 2022
Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Simon Galmiche¹, Benjamin Thoreau², Stéphane Bretagne³, Alexandre Alanio³, André Paugam⁴, Valérie Bru⁵, Sophie Cassaing⁶, Jean-Pierre Gangneux⁷, Hélène Guégan⁷, Loïc Favennec⁸, Alida Minoza⁹, Florent Morio¹⁰, Julie Bonhomme¹¹, Guillaume Desoubeaux¹², Odile Eloy¹³, Lilia Hasseine¹⁴, Milène Sasso¹⁵, Laurence Millon¹⁶, Anne-Pauline Bellanger¹⁶, Philippe Poirier¹⁷, Maxime Moniot¹⁷, Taieb Chouaki¹⁸, Antoine Huguenin¹⁹, Frédéric Dalle²⁰, Bernard Bouteille²¹, Muriel Nicolas²², Nicole Desbois-Nogard²³, Marie-Elisabeth Bougnoux²⁴, François Danion²⁵, Vincent Poindron²⁶, Antoine Néel²⁷, Karine Boukris-Sitbon²⁸, Fanny Lanternier²⁹ and Benjamin Terrier³⁰, ¹Institut Pasteur, Paris, France, ²AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, ³Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, ⁴Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, ⁵Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, ⁶Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, ⁷Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, ⁸French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, ⁹Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, ¹⁰Parasitologe – Mycologie, CHU de Nantes, Nantes, France, ¹¹Microbiologie, CHU de Caen, Caen, France, ¹²Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, ¹³Microbiologie, Hôpital de Versailles, Le Chesnay, France, ¹⁴Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, ¹⁵Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, ¹⁶Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, ¹⁷Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁸Mycologie – parasitologie, CHU d’Amiens, Amiens, France, ¹⁹Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, ²⁰Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, ²¹Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, ²²Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, ²³Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, ²⁴Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, ²⁵Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁷CHU de Nantes, Nantes, France, ²⁸Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, ²⁹Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, ³⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Bryant England¹, Michael George², Yangyuna Yang¹, Punyasha Roul³, Jorge Rojas⁴, Brian Sauer⁵, Grant Cannon⁶, Joshua Baker⁷, Jeffrey Curtis⁸ and Ted Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].